- Home
- FULC vs CMPS Comparison
FULC vs CMPS Comparison
Compare FULC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- CMPS
- Stock Information
- Founded
- FULC 2015
- CMPS 2020
- Country
- FULC United States
- CMPS United Kingdom
- Employees
- FULC N/A
- CMPS N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- FULC Health Care
- CMPS Health Care
- Exchange
- FULC Nasdaq
- CMPS Nasdaq
- Market Cap
- FULC 372.2M
- CMPS 364.9M
- IPO Year
- FULC 2019
- CMPS 2020
- Fundamental
- Price
- FULC $6.40
- CMPS $4.83
- Analyst Decision
- FULC Buy
- CMPS Strong Buy
- Analyst Count
- FULC 8
- CMPS 7
- Target Price
- FULC $7.13
- CMPS $17.00
- AVG Volume (30 Days)
- FULC 420.8K
- CMPS 1.5M
- Earning Date
- FULC 07-29-2025
- CMPS 10-30-2025
- Dividend Yield
- FULC N/A
- CMPS N/A
- EPS Growth
- FULC N/A
- CMPS N/A
- EPS
- FULC N/A
- CMPS N/A
- Revenue
- FULC N/A
- CMPS N/A
- Revenue This Year
- FULC N/A
- CMPS N/A
- Revenue Next Year
- FULC N/A
- CMPS N/A
- P/E Ratio
- FULC N/A
- CMPS N/A
- Revenue Growth
- FULC 2752.05
- CMPS N/A
- 52 Week Low
- FULC $2.32
- CMPS $2.25
- 52 Week High
- FULC $9.30
- CMPS $7.74
- Technical
- Relative Strength Index (RSI)
- FULC 44.51
- CMPS 62.99
- Support Level
- FULC $6.36
- CMPS $4.40
- Resistance Level
- FULC $6.75
- CMPS $5.07
- Average True Range (ATR)
- FULC 0.30
- CMPS 0.28
- MACD
- FULC 0.01
- CMPS 0.03
- Stochastic Oscillator
- FULC 19.59
- CMPS 89.09
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.